Professor Andrew Wei is an internationally recognised leader in the field of acute myeloid leukaemia (AML). He has led nationwide trial development in Australia for 14 years as the AML chair for the ALLG. His laboratory has made pre-clinical contributions to the clinical development of BH3-mimetics in AML culminating in the regulatory approval of venetoclax by the FDA in 2020 and the Australian PBAC in 2021. Wei’s lab has conducted research studies investigating the molecular mechanisms of response and resistance to venetoclax-based therapy. He leads the AML program at the Peter MacCallum Cancer Centre and a research laboratory at WEHI.